Through ‘radical transparency,’ Kennedy can finally rein in Big Pharma
Kennedy can provide doctors and healthcare professionals with the information they need to truly determine if a drug is safe, ...
Sanctuary Advisors LLC Cuts Holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK)
Sanctuary Advisors LLC cut its position in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK – Free Report) by 57.9% ...
Protagonist And Takeda Announce Positive Topline Results From Phase 3 VERIFY Study Of Rusfertide In Patients With Polycy...
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX ) and Takeda (TSE:4502/NYSE:TAK ) today announced positive ...
BioPharma Dive2d
Protagonist says Takeda-partnered drug succeeds in rare blood cancer
Takeda paid Protagonist $300 million one year ago to license rights to rusfertide, which the companies are developing to ...
Takeda-Protagonist Therapeutics Partnered Investigational Drug Hits Primary Goal In Late-Stage Study In Patients With Type Of Blood Cancer
Rusfertide met all primary and secondary endpoints in a Phase 3 trial for polycythemia vera, with strong efficacy and safety ...
Zacks Investment Research on MSN3d
Should Value Investors Buy Takeda Pharmaceutical Co. (TAK) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest ...
BioSpace3d
Takeda-Protagonist Drug for Incurable Cancer Reduces Need for Blood Withdrawals in Phase III Trial
Protagonist Therapeutics notches a milestone in its pact with Takeda for rusfertide. New data show that many patients with a ...
Why were zebras parachuting from the rafters at a recent Celtics game?
Takeda Pharmaceutical teamed up with the Boston Celtics to raise awareness of rare diseases at the C’s-Cavaliers game on ...
Denali Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today reported financial results for the fourth quarter and year ended December 31, 2024, and ...